GSK’s Heart Drug Flops in Phase III Trial

Drug Industry Daily
A A
GlaxoSmithKline’s experimental coronary heart disease drug darapladib failed to reduce heart attacks, strokes and major cardiovascular events in a closely watched Phase III clinical trial, deflating some expectations for GSK’s Phase III pipeline.

To View This Article:

Login

Subscribe To Drug Industry Daily